Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01026220 |
|
Recruitment Status :
Completed
First Posted : December 4, 2009
Results First Posted : May 30, 2017
Last Update Posted : April 28, 2022
|
Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma Stage III Childhood Hodgkin Lymphoma Stage IV Childhood Hodgkin Lymphoma | Biological: bleomycin sulfate Drug: doxorubicin hydrochloride Drug: liposomal vincristine sulfate Drug: vinorelbine tartrate Drug: cyclophosphamide Drug: etoposide phosphate Drug: prednisone Biological: filgrastim Drug: ifosfamide | Phase 3 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 166 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma |
| Actual Study Start Date : | December 7, 2009 |
| Actual Primary Completion Date : | March 1, 2012 |
| Actual Study Completion Date : | March 31, 2022 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Regimen I (consolidation therapy)
Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
|
Biological: bleomycin sulfate
Given IV or SC
Other Names:
Drug: doxorubicin hydrochloride Given IV
Other Names:
Drug: liposomal vincristine sulfate Given IV
Other Names:
Drug: cyclophosphamide Given IV
Other Names:
Drug: etoposide phosphate Given IV
Other Names:
Drug: prednisone Given IV
Other Names:
Biological: filgrastim Given IV or SC
Other Names:
|
|
Experimental: Regimen II (consolidation therapy)
Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
|
Biological: bleomycin sulfate
Given IV or SC
Other Names:
Drug: doxorubicin hydrochloride Given IV
Other Names:
Drug: liposomal vincristine sulfate Given IV
Other Names:
Drug: vinorelbine tartrate Given IV
Other Names:
Drug: cyclophosphamide Given IV
Other Names:
Drug: etoposide phosphate Given IV
Other Names:
Drug: prednisone Given IV
Other Names:
Biological: filgrastim Given IV or SC
Other Names:
Drug: ifosfamide Given IV
Other Names:
|
|
Experimental: Induction: all patient
All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
|
Drug: doxorubicin hydrochloride
Given IV
Other Names:
Drug: liposomal vincristine sulfate Given IV
Other Names:
Drug: cyclophosphamide Given IV
Other Names:
Drug: etoposide phosphate Given IV
Other Names:
Drug: prednisone Given IV
Other Names:
Biological: filgrastim Given IV or SC
Other Names:
|
Primary Outcome Measures :
- Second-event-free Survival [ Time Frame: At 4 years from enrollment ]Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.
- Safety Analysis and Monitoring of Toxic Death [ Time Frame: Within 30 days of protocol treatment at median follow-up of 48 months (range: 1 to 70 months). ]The primary endpoint for safety analysis and monitoring is toxic death, which is death primarily attributable to treatment.
Secondary Outcome Measures :
- Event Free Survival [ Time Frame: At 3 years from enrollment ]Survival from enrollment to first event: relapse/progression, second malignancy, or death.
- Second-event-free Survival [ Time Frame: At 4 years from enrollment ]Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.
- Event-free Survival for Rapid Early Response (RER) Positron Emission Tomography(PET)-1 Positive, RER PET-1 Negative [ Time Frame: 3 years from enrollment ]To investigate whether very early response assessment measured by Fluorodeoxyglucose-PET after 1 cycle of chemotherapy identifies a subject cohort that can be studied in future trials and that is distinguishable from currently defined RER after 2 cycles.
- Relapse-free Survival [ Time Frame: 3 years from enrollment ]A description, survival to relapse, of patterns of relapse after Doxorubicin, Bleomycin, Vincristine, Etoposide - Prednisone, Cyclophosphamide (ABVE-PC) and risk-adapted radiotherapy.
- Grade 3 and 4 Non-hematologic Toxicities During Protocol Therapy [ Time Frame: During and after completion of study treatment. ]The number of patients that experience Common Terminology Criteria (CTC) Version 4 grade 3 or higher non-hematologic toxicity at any time during protocol therapy.
- Overall Survival [ Time Frame: At 3 years from enrollment ]Survival from enrollment to death.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 21 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Pathologically confirmed newly diagnosed Hodgkin lymphoma (HL) meeting one of the following criteria:
- Classical disease
- Nodular lymphocyte-predominant disease
-
Stage III or IV disease with B symptoms, as defined by ≥ 1 of the following:
- Unexplained weight loss > 10% within the past 6 months
- Unexplained recurrent fever > 38°C within the past month
- Recurrent drenching night sweats within the past month
-
Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR maximum serum creatinine based on age/gender as follows:
- 0.4 mg/dL (1 to 5 months)
- 0.5 mg/dL (6 to 11 months)
- 0.6 mg/dL (12 to 23 months)
- 0.8 mg/dL (2 to 5 years)
- 1 mg/dL (6 to 9 years)
- 1.2 mg/dL (10 to 12 years)
- 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years)
- 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years)
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- AST or ALT < 2.5 times ULN for age
- Shortening fraction ≥ 27% by ECHO OR ejection fraction ≥ 50% by MUGA (unless due to large mediastinal mass from HL)
-
FEV_1/FVC > 60% by pulmonary function tests (PFT) (unless due to large mediastinal mass fromHL)
-
For children who are unable to cooperate for PFTs, the criteria are:
- No evidence of dyspnea at rest
- No exercise intolerance
- Pulse oximetry > 92% on room air
-
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No pathologic prolongation of QTc interval (> 450 milliseconds) on 12-lead ECG
- No prior chemotherapy, biological response modifiers (e.g., monoclonal antibody therapy), or radiotherapy
- At least 28 days since prior corticosteroids except for emergent treatment for respiratory distress or spinal cord compression, or for treatment of allergy to contrast agent required for CT scan
-
No other concurrent cancer chemotherapy or immunomodulating agents (including steroids)
- Concurrent corticosteroid therapy as treatment or prophylaxis for anaphylactic reactions allowed
- No concurrent pegfilgrastim
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01026220
Locations
Show 177 study locations
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Kara Kelly, MD | Children's Oncology Group |
Additional Information:
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT01026220 |
| Other Study ID Numbers: |
AHOD0831 NCI-2011-01994 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) CDR0000660550 AHOD0831 ( Other Identifier: Children's Oncology Group ) AHOD0831 ( Other Identifier: CTEP ) U10CA098543 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 4, 2009 Key Record Dates |
| Results First Posted: | May 30, 2017 |
| Last Update Posted: | April 28, 2022 |
| Last Verified: | December 2021 |
Additional relevant MeSH terms:
|
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Prednisone Cyclophosphamide Ifosfamide Doxorubicin Liposomal doxorubicin Etoposide Vincristine |
Vinorelbine Bleomycin Etoposide phosphate Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors |